U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 871 - 880 of 34988 results

Status:
Investigational
Source:
INN:girisopam [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Girisopam (GYKI 51189), a 2,3-benzodiazepine, is a compound with anxiolytic and antipsychotic action. It has shown these effects in several animal models. Girisopam differs from the traditional 1,4-benzodiazepines because of its selective anxiolytic action without muscle relaxant and anticonvulsive activity, and because it does not have affinity for 1,4-benzodiazepine receptors. Antidepressant activity of girisopam was also reported. The binding site of girisopam in neuronal cells in the central nervous system is located exclusively to the basal ganglia. Because the danger of tolerance and dependence is lower for 2,3-benzodiazepine than 1,4-benzodiazepines, girisopam may potentially be used in treatment of addiction and affective disorders. No clinical trials were conducted in the US.
Status:
Investigational
Source:
INN:sulazepam
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Sulazepam is a desmethylbenzodiazepine. It is the thioamide derivative of diazepam. It has sedative, muscle relaxant, hypnotic, anticonvulsant and anxiolytic properties like those of other benzodiazepines. Sulazepam in vivo in experimental animals undergoes enzymic desulfonation, demethylation, and [3C] hydroxylation, with the formation of basic metabolites: diazepam, desmethyldiazepam, and oxazepam.
Status:
Investigational
Source:
INN:lucartamide [INN]
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Lucartamide is an antisecretory and antiulcer agent.
Status:
Investigational
Source:
INN:lotucaine
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Lotucaine is a local anesthetic.
Status:
Investigational
Source:
NCT00442780: Phase 2 Interventional Completed Parkinson's Disease
(2007)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)



Vipadenant (V2006) is a small molecule, adenosine A2A receptor antagonist that was being investigated in Parkinson's disease. Due to safety concerns development ceased in 2010 and the rights were regained from Biogen Idec in 2011 with no further investment made. In October 2014, RedoxTherapies licensed Vipadenant as it has the potential to disrupt an immunosuppressive mechanism of tumour protection, generating improved efficacy for immunotherapies of certain cancers when used in combination with other drugs.
Status:
Investigational
Source:
INN:bicozamycin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Bicyclomycin has been used to treat diarrhea in humans and bacterial diarrhea in calves and pigs and is marketed by Fujisawa (Osaka, Japan) under the trade name Bicozamycin. This drug is the selective inhibitor of rho, a member of the RecA-type ATPase class of enzymes that use nucleotide contacts to couple oligonucleotide translocation to ATP hydrolysis.
Status:
Investigational
Source:
NCT03585270: Phase 3 Interventional Completed Aneurysmal Subarachnoid Hemorrhage
(2019)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Clazosentan is an endothelin receptor antagonist, developed by the Swiss pharmaceutical company Actelion, and licensed to its spin-off, Idorsia. The drug was designed to inhibit endothelin-mediated cerebral vasospasm and associated delayed ischaemic neurological deficit. The drug has been investigated in a phase III clinical trials in patients with aneurysmal subarachnoid hemorrhage. Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome. Clinical investigation of a higher dose of the drug is underway.
Status:
Investigational
Source:
INN:biclofibrate
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Biclofibrate was investigated as an antilipidemic agent.
Status:
Investigational
Source:
INN:necopidem
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Necopidem, a zolpidem derivative, is an anxiolytic and sedative drug.
Status:
Investigational
Source:
INN:clemeprol [INN]
Source URL:

Class (Stereo):
CHEMICAL (MIXED)

Clemeprol is an antidepressant drug of the 3,3-diraylpropyl-amine type. It exhibits antireserpine activity in animal tests, inhibits the neuronal uptake of noradrenaline. The drug was used in the clinic for the treatment of depression in the 1980s, but no development was reported since.